MAPT and Alzheimer disease: Novel small molecular compound 2JY-OBZ4 was found to act on multiple AD related pathological phenomena, such as tau hyperphosphorylation, Aβ toxicity and decreased acetylcholine (ACh), making it a member of combination therapies.